We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Regulatory News : BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), Société d’innovation dédiée aux produits orphelins en cancérologie et aux produits de spécialité, annonce...
First semester 2013 Grant of the Marketing Authorization for Sitavig® in the US Strong achievements in clinical trials with Livatag® (phase III) and Validive® (phase II...
Regulatory News : BioAlliance Pharma (Paris:BIO) : Pursuant to article L.233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général...
Regulatory News : BioAlliance Pharma (Paris:BIO) : Conformément à l’article L. 233-8 II du Code de commerce et à l’article 223-16 du Règlement général de l’Autorité des Marchés...
Montant brut levé : 8,7 millions d’euros ; Opération sursouscrite à hauteur de 155 % ; Exercice de la clause d’extension.
Regulatory News: BioAlliance Pharma SA (Paris:BIO), an innovative Company dedicated to the development of orphan oncology products and supportive care products, announces it was...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions